Clinical Trials Browser

Phase 1 × INDUSTRY × atezolizumab × Clear all

NCT06496568 2026-04-16

A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab, and Inavolisib Plus Pembrolizumab in PIK3CA-Mutated Cancers

Phase 1 Recruiting

30 enrolled

PIK3CA-Mutated Cancers

NCT05581004 2026-04-15

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

450 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms

NCT06077500 2026-04-14

DAREONᵀᴹ-8

Phase 1 Active not recruiting

46 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT05595460 2026-04-13

Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC

Phase 1 Active not recruiting

21 enrolled

Thoracic

SCLC,Extensive Stage

NCT07190833 2026-04-09

A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)

Phase 1 Recruiting

27 enrolled

Other solid neoplasm

Treatment-Refractory Solid Tumors

NCT06444815 2026-04-07

STEALTH-001

Phase 1 Recruiting

60 enrolled

DermatologicGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Kidney Neoplasms, Melanoma, Mesothelioma

NCT07170592 2026-04-07

A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients

Phase 1 Not yet recruiting

24 enrolled

Other solid neoplasm

Treatment-Refractory Solid Tumors

NCT06031441 2026-04-03

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

250 enrolled

Other solid neoplasm

Locally Advanced Solid Tumors

NCT06179069 2026-04-03

A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

Phase 1 Recruiting

339 enrolled

Thoracic

SCLC

Clinical Trials

A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab, and Inavolisib Plus Pembrolizumab in PIK3CA-Mutated Cancers

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

DAREONᵀᴹ-8

Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC

A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)

STEALTH-001

A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors

An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

(DeLLphi-310)

A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010

Trial of INI-4001 in Patients With Advanced Solid Tumours

IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors

PanTumor-101

LB-LR1109

EIK1001

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors

Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)

A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.

FORT-2

A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors

ACTolog

Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors

Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors

STELLAR-001

Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors

A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

A Study of KF-0210 in Advanced Solid Tumors Patients

A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma

LAM-002A/NHL

A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma

A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.

Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases

Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants

PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors

A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors

A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors